Tevogen (TVGN) Advances Acquisition Plans, Sees $100M Annual Revenue Boost

Tevogen Inc. (NASDAQ: TVGN) said Thursday it is advancing strategic acquisition plans that are expected to add approximately $100 million in annual revenue, a move aimed at transitioning the biotechnology company into a commercial-stage enterprise. The acquisition target, which remains undisclosed, would bring a revenue-generating asset to Tevogen’s portfolio and strengthen its oncology pipeline, according to a company statement. Tevogen executives said the deal is in advanced negotiations, though no definitive agreement has been signed. The company went public in 2024 and has since been seeking to move beyond its development-stage status. The potential $100 million revenue contribution would mark a significant shift from Tevogen’s current pre-revenue operations. Shares of Tevogen were flat in early trading Thursday. The acquisition would be Tevogen’s first major transaction since its listing.